Slides on Key Decisions in HIV Care: Considering Tenofovir Alafenamide in Pregnancy

Learn the latest data about whether to use tenofovir alafenamide during pregnancy.
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Format: Microsoft PowerPoint (.ppt)
File Size: 351 KB
Released: September 24, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

person default Ariel Campos, MD person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Luis E. Soto-Ramirez, MD Released: June 21, 2022

Clinical Care Options (CCO) presents expert faculty discussing the barriers and solutions to expanding PrEP uptake, from a nursing perspective

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
person default Christopher Fox, MSN, RN, ANP-BC, AAHIVS
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 14, 2022 Expired: June 13, 2023

Expert analysis of barriers and solutions to PrEP uptake in key populations

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Released: May 31, 2022

Breve vlog del Dr. Luis E. Soto-Ramírez sobre la optimización del TAR en una paciente con VIH en edad fértil en México de Clinical Care Options (CCO)

Luis E. Soto-Ramirez, MD Released: May 31, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings